D
Addex Therapeutics Ltd
ADXN
$7.30
-$0.15-2.01%
D
Sell
11/29/2024Downgrade
Addex Therapeutics Ltd (ADXN) was downgraded to D from D+ on 11/29/2024 due to a large decline in the growth index and volatility index. Earnings per share declined from $0.1449 to -$0.0232, and total revenue declined 47.06% from $127.5 to $67.5.
Addex Therapeutics Ltd (ADXN) was downgraded to D from D+ on 11/29/2024 due to a large decline in the growth index and volatility index. Earnings per share declined from $0.1449 to -$0.0232, and total revenue declined 47.06% from $127.5 to $67.5.
D
Sell
10/23/2024Upgraded
Addex Therapeutics Ltd (ADXN) was upgraded to D+ from D on 10/23/2024 due to an increase in the total return index and volatility index.
Addex Therapeutics Ltd (ADXN) was upgraded to D+ from D on 10/23/2024 due to an increase in the total return index and volatility index.
D
Sell
10/2/2024Upgraded
Addex Therapeutics Ltd (ADXN) was upgraded to D from E+ on 10/2/2024 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 0.4 to 4.67, total capital increased 1,051.7% from -$1.48M to $14.11M, and net income increased 503.35% from -$3.53M to $14.24M.
Addex Therapeutics Ltd (ADXN) was upgraded to D from E+ on 10/2/2024 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 0.4 to 4.67, total capital increased 1,051.7% from -$1.48M to $14.11M, and net income increased 503.35% from -$3.53M to $14.24M.
E
Sell
3/14/2023Downgrade
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and valuation index.
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and valuation index.
D
Sell
1/31/2023Upgraded
Addex Therapeutics Ltd (ADXN) was upgraded to D- from E+ on 1/31/2023 due to an increase in the volatility index and total return index.
Addex Therapeutics Ltd (ADXN) was upgraded to D- from E+ on 1/31/2023 due to an increase in the volatility index and total return index.
E
Sell
1/13/2023Downgrade
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D- on 1/13/2023 due to a decline in the valuation index.
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D- on 1/13/2023 due to a decline in the valuation index.
D
Sell
12/21/2022Upgraded
Addex Therapeutics Ltd (ADXN) was upgraded to D- from E+ on 12/21/2022 due to an increase in the valuation index.
Addex Therapeutics Ltd (ADXN) was upgraded to D- from E+ on 12/21/2022 due to an increase in the valuation index.
E
Sell
12/6/2022Downgrade
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D- on 12/6/2022 due to a decline in the volatility index.
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D- on 12/6/2022 due to a decline in the volatility index.
D
Sell
11/18/2022Upgraded
Addex Therapeutics Ltd (ADXN) was upgraded to D- from E+ on 11/18/2022 due to an increase in the growth index and valuation index. Total revenue increased 122.67% from $193.2 to $430.2, earnings per share increased from -$0.1997 to -$0.089, and operating cash flow increased 53.91% from -$6.04M to -$2.78M.
Addex Therapeutics Ltd (ADXN) was upgraded to D- from E+ on 11/18/2022 due to an increase in the growth index and valuation index. Total revenue increased 122.67% from $193.2 to $430.2, earnings per share increased from -$0.1997 to -$0.089, and operating cash flow increased 53.91% from -$6.04M to -$2.78M.
E
Sell
4/20/2022Downgrade
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
3/15/2022Downgrade
Addex Therapeutics Ltd (ADXN) was downgraded to D- from D on 3/15/2022 due to a substantial decline in the growth index, volatility index and total return index. Total revenue declined 47.26% from $825.2 to $435.2, earnings per share declined from -$0.1148 to -$0.138, and EBIT declined 19.09% from -$3.89M to -$4.64M.
Addex Therapeutics Ltd (ADXN) was downgraded to D- from D on 3/15/2022 due to a substantial decline in the growth index, volatility index and total return index. Total revenue declined 47.26% from $825.2 to $435.2, earnings per share declined from -$0.1148 to -$0.138, and EBIT declined 19.09% from -$3.89M to -$4.64M.
D
Sell
11/9/2021Upgraded
Addex Therapeutics Ltd (ADXN) was upgraded to D from E+ on 11/09/2021.
Addex Therapeutics Ltd (ADXN) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index and total return index. The quick ratio declined from 5.26 to 4.91.
Addex Therapeutics Ltd (ADXN) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index and total return index. The quick ratio declined from 5.26 to 4.91.
D
Sell
2/1/2021Upgraded
Addex Therapeutics Ltd (ADXN) was upgraded to D from D- on 2/1/2021 due to an increase in the solvency index and volatility index. Debt to equity declined from 0.02 to 0.01, and the quick ratio increased from 7.42 to 8.1.
Addex Therapeutics Ltd (ADXN) was upgraded to D from D- on 2/1/2021 due to an increase in the solvency index and volatility index. Debt to equity declined from 0.02 to 0.01, and the quick ratio increased from 7.42 to 8.1.
D
Sell
10/1/2020Upgraded
Addex Therapeutics Ltd (ADXN) was upgraded to D- from E on 10/1/2020 due to a large increase in the growth index, volatility index and total return index. EBIT increased 30.12% from -$4.42M to -$3.09M, and earnings per share increased from -$0.1673 to -$0.1212.
Addex Therapeutics Ltd (ADXN) was upgraded to D- from E on 10/1/2020 due to a large increase in the growth index, volatility index and total return index. EBIT increased 30.12% from -$4.42M to -$3.09M, and earnings per share increased from -$0.1673 to -$0.1212.
E
Sell
7/1/2020Upgraded
Addex Therapeutics Ltd (ADXN) was upgraded to E from E- on 7/1/2020 due to an increase in the volatility index and total return index.
Addex Therapeutics Ltd (ADXN) was upgraded to E from E- on 7/1/2020 due to an increase in the volatility index and total return index.
E
Sell
6/3/2020None
Addex Therapeutics Ltd (ADXN) was downgraded to E- from U on 06/03/2020.
Addex Therapeutics Ltd (ADXN) was downgraded to E- from U on 06/03/2020.
NASDAQ
04/03/2025 3:54PM Eastern
Quotes delayed
